Small molecule · developed by Ligand Pharmaceuticals
Aplindore is an oral tablet studied in early stage Parkinson's disease, dosed at 0.05 to 5 mg twice daily.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00623324 | Phase 2 | Early Stage Parkinson's Disease | Completed | LGND |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Early Stage Parkinson's Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.
See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LGND catalysts and pipeline →